CervoMed Inc. — Director's Dealing 2022

Aug 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2022-08-01

Reporting Person: Cobuzzi Robert Joseph Jr. (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-01	Common Stock	M	327	—	Acquired	1325	Direct
2022-08-01	Common Stock	D	121	—	Disposed	1204	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-01	Restricted Stock Unit	$	M	327	Disposed		Common Stock (327)	Direct

Footnotes

F1: On August 1, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 206 Shares and (ii) $787.71 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.51. The remainder of the award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer.

All share, per share, and share-based amounts reflect the Issuer's 1-for-50 reverse stock split implemented April 18, 2022.